Physician profile
William C Lopez
NPI 1013998228
$6,804.23
in general payments reported to CMS, 2019-2025
32 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $125 · 2021: $781 · 2022: $1,015 · 2023: $950 · 2024: $1,768 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172 · Education: $54.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.22 |
| Education | $54.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,201.97 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $604.05 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $567.68 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $373.41 | 2021-2025 | |
| Madrigal Pharmaceuticals | $296.21 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $267.22 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $227.13 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $218.24 | 2019-2025 | |
| Celltrion USA INC. | $194.57 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $193.47 | 2024-2025 | Voquezna |
| Celgene Corporation | $156.93 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $150.54 | 2019-2024 | Linzess |
| Ardelyx, INC. | $136.65 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $130.60 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $128.15 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $126.18 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $83.90 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $65.24 | 2023-2024 | Ocaliva |
| Evoke Pharma, INC. | $64.10 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $60.37 | 2022-2023 | |
| Amgen INC. | $39.14 | 2025 | Uplizna |
| Lilly USA, LLC | $37.88 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $35.26 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $32.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.01 | 2023 | |
| Ucb, INC. | $25.02 | 2019 | |
| Enterra Medical, INC. | $23.70 | 2024 | |
| Mallinckrodt Hospital Products INC. | $20.57 | 2024 | Terlivaz |
| Shire North American Group INC | $15.75 | 2019 | |
| Alfasigma USA, INC. | $14.12 | 2022 | |
| Exact Sciences Corporation | $13.55 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.